Integrated Safety and Efficacy Analysis of FMX103 1.5% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea: Results From Two Phase 3 Studies

Main Article Content

James Q Del Rosso
Linda Stein Gold
Leon Kircik
Neal D Bhatia
Neil Sadick
Matthew Zirwas
Edward Lain
Iain Stuart

Keywords

Rosacea papulopustular, Minocycline, Foam, Efficacy, Safety

Abstract

Abstract not available.

References

1. Li WQ, Cho E, Khalili H, et al. Rosacea, use of tetracycline, and risk of incident of inflammatory bowel disease in women. Clin Gastroenterol Hepatol. 2016;14(2):220-225.

2. Taieb A, Gold LS, Feldman SR, et al. Cost-effectiveness of ivermectin 1% cream in adults with papulopustular rosacea in the United States. J Manag Care Spec Pharm. 2016;22(6):654-665.

3. Rainer BM, Kang S, Chien AL. Rosacea: epidemiology, pathogenesis, and treatment. Dermatoendocrinol. 2017;9(1):e1361574.

4. Oge LK, Muncie HL, Phillips-Savoy AR. Rosacea: diagnosis and treatment. Am Acad Fam Physicians. 2015;92(3):187-196.

5. Schaller M, Schofer H, Homey B, et al. Rosacea management: update on general measures and topical treatment options. J Dtsch Dermatol Ges. 2016;14(S6):17-27.

6. Sapadin AN , Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006;54:258-65.

7. Mrowietz U, Kedem TH, Keynan R, et al. A phase II, randomized, double-blind clinical study evaluating the safety, tolerability, and efficacy of a topical minocycline foam, FMX103, for the treatment of facial papulopustular rosacea. Am J Clin Dermatol. 2018;19(3)427-436.

8. Stein Gold L, Del Rosso JQ, Kircik L, et al. Minocycline 1.5% foam for the topical treatment of moderate-to-severe papulopustular rosacea: Results of two phase 3, Randomized, Clinical Trials. J Am Acad Dermatol. 2020; doi: 10.1016/j.jaad.2020.01.043